BACKGROUND: Quality improvement programs have shown increased use of beta-blockers post-myocardial infarction (MI), but there are no data on whether appropriate doses are administered. METHODS: In a prospective registry that enrolled consecutive patients with MI, we evaluated beta-blocker dosing at discharge after MI and 3 weeks later and assessed clinical predictors for treatment with very low doses. We studied 1,971 patients (70.8% male) with a mean age of 63.9 +/- 13.7 years, of whom 48.2% had an ST-elevation MI. RESULTS:beta-Blocker utilization rates following MI were 93.2% at discharge: 20.1% received <25% of target dose, 36.5% received 25% of target dose, 26.4% received 26% to 50% of target dose, and 17.0% received >50% of target dose. Between discharge and 3 weeks, 76.4% had no change in beta-blocker dose, with 11.9% and 11.6% having their dose reduced and increased, respectively. Absence of hypertension, acute percutaneous coronary intervention, older age, and no angiotensin-converting enzyme inhibitor therapy were consistent predictors of treatment with very low beta-blocker doses. CONCLUSIONS: Underdosing of beta-blockers is highly prevalent among patients post-MI. This represents an important opportunity in quality improvement for the care of patients who have suffered an MI. 2010 Mosby, Inc. All rights reserved.
RCT Entities:
BACKGROUND: Quality improvement programs have shown increased use of beta-blockers post-myocardial infarction (MI), but there are no data on whether appropriate doses are administered. METHODS: In a prospective registry that enrolled consecutive patients with MI, we evaluated beta-blocker dosing at discharge after MI and 3 weeks later and assessed clinical predictors for treatment with very low doses. We studied 1,971 patients (70.8% male) with a mean age of 63.9 +/- 13.7 years, of whom 48.2% had an ST-elevation MI. RESULTS: beta-Blocker utilization rates following MI were 93.2% at discharge: 20.1% received <25% of target dose, 36.5% received 25% of target dose, 26.4% received 26% to 50% of target dose, and 17.0% received >50% of target dose. Between discharge and 3 weeks, 76.4% had no change in beta-blocker dose, with 11.9% and 11.6% having their dose reduced and increased, respectively. Absence of hypertension, acute percutaneous coronary intervention, older age, and no angiotensin-converting enzyme inhibitor therapy were consistent predictors of treatment with very low beta-blocker doses. CONCLUSIONS: Underdosing of beta-blockers is highly prevalent among patients post-MI. This represents an important opportunity in quality improvement for the care of patients who have suffered an MI. 2010 Mosby, Inc. All rights reserved.
Authors: A Hjalmarson; D Elmfeldt; J Herlitz; S Holmberg; I Málek; G Nyberg; L Rydén; K Swedberg; A Vedin; F Waagstein; A Waldenström; J Waldenström; H Wedel; L Wilhelmsen; C Wilhelmsson Journal: Lancet Date: 1981-10-17 Impact factor: 79.321
Authors: Brian W Jack; Veerappa K Chetty; David Anthony; Jeffrey L Greenwald; Gail M Sanchez; Anna E Johnson; Shaula R Forsythe; Julie K O'Donnell; Michael K Paasche-Orlow; Christopher Manasseh; Stephen Martin; Larry Culpepper Journal: Ann Intern Med Date: 2009-02-03 Impact factor: 25.391
Authors: Kornelia Kotseva; David Wood; Guy De Backer; Dirk De Bacquer; Kalevi Pyörälä; Ulrich Keil Journal: Eur J Cardiovasc Prev Rehabil Date: 2009-04
Authors: John Wikstrand; Ake Hjalmarson; Finn Waagstein; Björn Fagerberg; Sidney Goldstein; John Kjekshus; Hans Wedel Journal: J Am Coll Cardiol Date: 2002-08-07 Impact factor: 24.094
Authors: P J Devereaux; Homer Yang; Salim Yusuf; Gordon Guyatt; Kate Leslie; Juan Carlos Villar; Denis Xavier; Susan Chrolavicius; Launi Greenspan; Janice Pogue; Prem Pais; Lisheng Liu; Shouchun Xu; German Málaga; Alvaro Avezum; Matthew Chan; Victor M Montori; Mike Jacka; Peter Choi Journal: Lancet Date: 2008-05-12 Impact factor: 79.321
Authors: Elliott M Antman; Daniel T Anbe; Paul Wayne Armstrong; Eric R Bates; Lee A Green; Mary Hand; Judith S Hochman; Harlan M Krumholz; Frederick G Kushner; Gervasio A Lamas; Charles J Mullany; Joseph P Ornato; David L Pearle; Michael A Sloan; Sidney C Smith; Joseph S Alpert; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Gabriel Gregoratos; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs Journal: Circulation Date: 2004-08-03 Impact factor: 29.690
Authors: Suzann Pershing; Nidhi Talwar; Stephen T Armenti; Joseph Grubbs; Julie M Rosenthal; Vaidehi S Dedania; Joshua D Stein Journal: Am J Ophthalmol Date: 2019-05-15 Impact factor: 5.258
Authors: Jeffrey J Goldberger; Robert O Bonow; Michael Cuffe; Lei Liu; Yves Rosenberg; Prediman K Shah; Sidney C Smith; Haris Subačius Journal: J Am Coll Cardiol Date: 2015-09-29 Impact factor: 24.094
Authors: Alexandre de Matos Soeiro; Pedro Gabriel Melo de Barros E Silva; Eduardo Alberto de Castro Roque; Aline Siqueira Bossa; Cindel Nogueira Zullino; Sheila Aparecida Simões; Mariana Yumi Okada; Tatiana de Carvalho Andreucci Torres Leal; Maria Carolina Feres de Almeida Soeiro; Carlos V Serrano; Múcio Tavares Oliveira Journal: Clinics (Sao Paulo) Date: 2016-11-01 Impact factor: 2.365
Authors: Anna Meta Dyrvig Kristensen; Ann Bovin; Ann Dorthe Zwisler; Charlotte Cerquira; Christian Torp-Pedersen; Hans Erik Bøtker; Ida Gustafsson; Karsten Tange Veien; Kristian Korsgaard Thomsen; Michael Hecht Olsen; Mogens Lytken Larsen; Olav Wendelboe Nielsen; Per Hildebrandt; Sussie Foghmar; Svend Eggert Jensen; Theis Lange; Thomas Sehested; Tomas Jernberg; Dan Atar; Borja Ibanez; Eva Prescott Journal: Trials Date: 2020-05-23 Impact factor: 2.279